GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
Hagens Berman announced it is investigating claims against GRAIL regarding the NHS-Galleri Trial and encouraging investors to contact the firm regarding losses. The class period runs from May 13, 2025 to February 19, 2026, centered on allegations that GRAIL misled investors about the trial's design and primary endpoint.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.